Immunic Puts Progressive Multiple Sclerosis Research On Its Webinar Agenda
The drug developer’s most advanced candidate is in late-stage testing for relapsing multiple sclerosis.
Immunic, which develops oral drug candidates for neurological and gastrointestinal diseases, scheduled a Thursday webinar on progressive multiple sclerosis research and development. The company supplied a presentation for the event in an SEC filing Thursday; its most advanced candidate, vidofludimus calcium, is already in late-stage trials for relapsing multiple sclerosis.
Progressive MS On The Agenda
The webinar agenda centers on progressive multiple sclerosis, while Immunic’s most advanced clinical program addresses the relapsing form of the disease. The company intended to use its research presentation during the video conference.
Immunic identifies the feasibility of taking vidofludimus calcium into a confirmatory late-stage trial for progressive multiple sclerosis among its forward-looking statements. That potential development step remains distinct from the candidate’s existing late-stage trials for relapsing multiple sclerosis.
The company cautions that findings from earlier laboratory studies and clinical trials may not predict future trial results. Its expectations also cover whether vidofludimus calcium can safely and effectively treat the diseases it targets, as well as trial timing and regulatory approvals.
A Pipeline Without Product Sales
Immunic’s business is still drug development rather than commercial product sales. According to its annual report for the fiscal year ended December 31, 2025, the company has no products approved for sale and has generated no revenue from product sales.
Its research extends beyond multiple sclerosis. The pipeline includes IMU-856, designed to restore the intestinal barrier, and IMU-381, which is in preclinical testing for neurological, gastrointestinal and other autoimmune diseases. Chronic inflammatory and autoimmune conditions are part of the company’s broader development focus.
Immunic is headquartered in New York City, with its main operations near Munich, Germany. It had 92 employees as of February 1, 2026.
For those development programs, Immunic lists access to sufficient financial and other resources, the drug-approval process, intellectual-property protection and competing products among the risks to meeting its objectives.
The Thursday webinar was scheduled for 12:30 p.m. to 2:00 p.m. ET, with progressive multiple sclerosis research as its focus.
Sources
- 8-K Filing — IMMUNIC, INC. (IMUX) — SEC EDGAR
- Immunic highlights progressive MS research and Phase 3 outlook at MSToronto2026 — Yahoo Finance